Miconazole extended-release - Vectans Pharma

Drug Profile

Miconazole extended-release - Vectans Pharma

Alternative Names: BA-001; Loramyc; Miconazole extended-release - Onxeo; Miconazole Lauriad 50mg Bioadhesive Extended-Release Buccal Tablets; Miconazole Lauriad Bioadhesive Buccal Tablets; Miconazole Lauriad®; Oravig; Sitamic; SO-1105

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator BioAlliance Pharma
  • Developer SciClone Pharmaceuticals; Sosei; Vectans Pharma
  • Class Antifungals; Imidazoles; Small molecules
  • Mechanism of Action Cell membrane modulators; Cholesterol synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Oropharyngeal candidiasis

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for clinical-Phase-Unknown development in Oropharyngeal candidiasis in China (Buccal, Controlled release)
  • 31 Jul 2017 Vectans Pharma acquires Miconazole extended release from Onxeo
  • 28 Feb 2017 Preregistration for Oropharyngeal candidiasis in Japan (Buccal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top